Premium
Imatinib mesylate (STI571) treatment in patients with chronic‐phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
Author(s) -
Cervantes Francisco,
HernándezBoluda JuanCarlos,
Odriozola Jesús,
Camós Mireia,
Villalón Lucía,
MartínezCliment JoséAngel,
Del Campo Raquel,
GarcíaConde Javier,
Montserrat Emilio
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04077.x
Subject(s) - medicine , imatinib mesylate , chronic myelogenous leukemia , imatinib , gastroenterology , transplantation , rash , neutropenia , chemotherapy , surgery , leukemia , myeloid leukemia
Summary. Imatinib mesylate (STI571) is a highly effective and well‐tolerated treatment for patients with chronic‐phase chronic myeloid leukaemia (CML), but information on its efficacy and tolerance in intensively pretreated patients is scarce. Thirty‐three chronic‐phase CML patients who were resistant or intolerant to interferon (IFN) and had been previously submitted to autologous stem cell transplantation were treated with imatinib for a median of 14 months (range: 6–19 months). Seven patients were in haematological response (HR) at the start of treatment; the remaining 26 attained a HR at a median of 3 weeks (range: 1–4 weeks). Major cytogenetic response rates at 3, 6 and 12 months were 42%, 45% and 55%, respectively, including 21%, 24% and 33% complete responses. Grade 3–4 neutropenia, thrombocytopenia and anaemia developed in 33%, 27% and 12% of patients respectively. Non‐haematological toxicity included superficial oedema (21% of patients), gastrointestinal symptoms (18%), muscle cramps (15%), skin rash and liver enzyme increase (3% each). These results were not significantly different from those in 65 chronic‐phase CML patients, resistant or intolerant to interferon without a previous ASCT, who were included in the same protocol. Imatinib mesylate is effective and safe in chronic‐phase CML patients with a previous history of intensive treatment.